Amsterdam UMC - Amsterdam Neuroscience

What Amsterdam UMC - Amsterdam Neuroscience does

Amsterdam UMC is a public university medical center formed in 2018 through the merger of VUmc and AMC, operating two hospital campuses in Amsterdam (AMC at Meibergdreef 9 and VUmc at De Boelelaan 1117). The institution integrates clinical care, fundamental and translational research, and medical education, treating approximately 35,000 patients annually across specialties including oncology, cardiovascular disease, neurology, infectious disease, and pediatrics through its Emma Kinderziekenhuis subsidiary. Research is organized across eight specialized institutes — Amsterdam Neuroscience, Cancer Center Amsterdam, Amsterdam Cardiovascular Sciences, AGEM, Amsterdam Institute for Immunology and Infectious Diseases, Amsterdam Movement Sciences, Amsterdam Public Health, and Amsterdam Reproduction & Development — supported by nine core research facilities including a CRISPR Center, a centralized Biobank, a Research Imaging Core with a 7 Tesla MRI scanner, an iPSC platform, functional genomic screening, metabolomics, microscopy/cytometry, and OncoProteomics.

The organization employs approximately 15,000–17,000 staff and operates through affiliated academic partnerships with VU Amsterdam and the University of Amsterdam. Core technology infrastructure includes Electronic Patient Record systems, advanced imaging, and research core facilities that enable both clinical operations and grant-funded research; it is not a commercial software or product vendor. In June 2026, Amsterdam UMC completed the world's first Phase 3 trial of an in vivo CRISPR therapy, marking a milestone in translating gene-editing research to clinical use.

Amsterdam UMC operates under the regulated Dutch healthcare system, deriving revenue primarily from reimbursement by Dutch health insurers (zorgverzekeraars) for patient care, supplemented by research grants and program funding from NWO, ZonMw, EU Horizon, ERC, and healthcare charities. Secondary revenue streams include medical education and PhD training, industry-sponsored clinical trials and contract research, and technology transfer (valorisation). Major recent grant wins include the €37.5 million INTERCEPT consortium on Crohn's disease (January 2025) and a €10M+ Horizon grant on obesity (November 2023). Distribution combines direct hospital care at both locations, specialized outpatient clinics (including transgender care via Gender Clinic partnership and cardiac optimization via CardioNoVo+), e-health tools such as HartWacht and IkHerstel, and EU-level research consortia across Europe and select global health programs in Africa.

Name

Amsterdam UMC - Amsterdam Neuroscience

Legal name

Amsterdam UMC

Website

https://amsterdamumc.org

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Amsterdam UMC is a Dutch public university medical center operating two Amsterdam hospital campuses, delivering specialized clinical care to ~35,000 patients annually while conducting neuroscience, oncology, and cardiovascular research across eight institutes and nine core facilities.

Ownership category

akta.pro rank

Product category

Academic Medical Center Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Colleges, Universities, and Professional Schools (611310), Medical and Diagnostic Laboratories (6215), Professional, Scientific, and Technical Services (54)

SIC

Services-Hospitals (8060), Services-General Medical & Surgical Hospitals, Nec (8062), Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)

akta.pro primary industry

Academic Medical Centers (AMCs) & Teaching Hospitals (HLAFAAAA)

akta.pro secondary industries

Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Health & Biomedical Research Universities (Academic Medical Center–Affiliated) (EDAHABAC), Clinical Trial Site Operations & Study Coordination (HLAGACAE)

Keywords

• Academic medical center
• Healthcare services
• Clinical research
• Medical education
• Translational research

Headquarters

HQ city

Amsterdam, Nh

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Healthcare Services Revenue: Reimbursement from Dutch health insurers (zorgverzekeraars) for patient care services under the regulated Dutch healthcare system. Services include hospital care, specialist consultations, diagnostics, and treatments covered by basic health insurance.
2. Research Grants and Funding: Funding from government bodies (NWO, ZonMw, EU Horizon programs), healthcare charities (KWF, Hartstichting), and private foundations for scientific research. Includes project grants, program funding, and infrastructure support.
3. Education and Training: Revenue from medical education programs, PhD training, continuing professional development courses, and fellowship programs for healthcare professionals.
4. Valorisation and Commercial Research: Income from industry collaborations, clinical trials with pharmaceutical companies, contract research, and technology transfer activities.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels8 records

Core offering

Amsterdam UMC is a public university medical center that delivers tertiary and complex patient hospital care through its two Amsterdam locations (AMC and VUmc) and Emma Kinderziekenhuis pediatric hospital, conducts fundamental, translational, and clinical research across eight specialized institutes, and trains medical and biomedical students through PhD and continuing education programs. Services are supported by nine core research facilities, including a CRISPR Center, biobank, 7 Tesla MRI, and omics platforms, and by digital tools such as HartWacht and IkHerstel apps. Research is funded through grants from NWO, ZonMw, EU Horizon, ERC, and healthcare charities, alongside industry-sponsored clinical trials.

Product overview

Amsterdam UMC is a university medical center comprising two locations (AMC and VUmc) that operates as a healthcare, research, and educational institution. It does not offer commercial products or software services. The organization conducts medical research through specialized research institutes including Amsterdam Neuroscience, and operates core research facilities such as Biobank, CRISPR Center, Functional Genomic Screening, Genomics, Induced Pluripotent Stem Cells, Metabolomics, Microscopy and Cytometry, OncoProteomics, and Research Imaging Core Center. Patient care services include treatment across various medical specialties including cancer, cardiovascular diseases, neurology, and more.

Differentiator

Problem solved

Functional benefit

Products and services

• Tertiary Hospital Care (AMC and VUmc locations)
• Emma Kinderziekenhuis Pediatric Care
• Amsterdam UMC Research and Core Facility Services
• Medical Education and Doctoral Training Programs
• HartWacht (HeartGuard) Remote Cardiac Monitoring
• IkHerstel Post-Surgery Recovery App
• Industry-Sponsored Clinical Trials and Contract Research Clinical trial services and contract research delivered for pharmaceutical and biotech industry partners, leveraging Amsterdam UMC's patient cohorts, biobank, and specialized research expertise. Includes participation in EU-funded consortia such as the 37.5M euro INTERCEPT program for Crohn's disease and the 10M+ euro Horizon obesity program.
• European Reference Network Coordination for Rare Diseases

Quantifiable outcome

• Treatment of approximately 35,000 patients annually across both locations
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

13 partnerships are on record, tiered minor, core and flagship.

• University of CambridgeminorStrategic or Co-development Partner · 1 August 2026CCA Travel Grant supporting PhD candidate Flavia Runello to visit Professor John Doorbar's laboratory for spatial omics research in head and neck cancer.
• CardioNoVo+minorStrategic or Co-development Partner · 1 February 2026Regional collaboration for cardiac care optimization, innovation, and reducing waiting times. Focus on providing cardiac care at the right location.
• Gender ClinicminorStrategic or Co-development Partner · 1 January 2026Partnership to reduce waiting times for transgender care by combining expertise and resources. Aims to improve access to gender-affirming treatments.
• Yale UniversitycoreStrategic or Co-development Partner · 1 June 2025International collaboration on obesity research studying brain responses to nutrients, published in Nature Metabolism. Combined expertise in metabolic research.
• Radboud UniversitycoreStrategic or Co-development Partner · 1 February 2025Joint research project on sugar barcodes instructing intestinal immune cells, funded by NWO Open Competition Domain Science-M2. Collaborative study of glycans and inflammatory bowel diseases.
• European INTERCEPT ConsortiumflagshipStrategic or Co-development Partner · 1 January 2025International consortium led by Amsterdam UMC investigating early detection and treatment of Crohn's disease. Funded by 37.5 million euro European grant. Includes multiple European research institutions.
• Dutch Colorectal Cancer GroupcoreStrategic or Co-development Partner · 1 January 2024Collaborative COLLISION trial on thermal ablation versus surgical removal of liver metastases in colorectal cancer patients. Results published in The Lancet Oncology.
• European Reference Networks (ERN)coreStrategic or Co-development Partner · 1 January 2024European Commission initiative for rare disease care coordination. Amsterdam UMC coordinates 2 of the 24 European Reference Networks, ensuring cross-border collaboration for rare disease patients.
• European Horizon Research ConsortiumflagshipStrategic or Co-development Partner · 1 November 2023European research consortium led by Amsterdam UMC investigating causes of obesity and designing intervention guidelines. Funded by more than 10 million euros through Horizon grant.
• VU AmsterdamcoreStrategic or Co-development PartnerCoordinating institution for Amsterdam UMC combining academic medical center functions with VU University's research and education capabilities. Joint PhD programs and research collaborations across medical and biomedical sciences.
• University of Amsterdam (UvA)coreStrategic or Co-development PartnerAcademic partner through AMC location, providing medical education and research collaboration. Joint supervision of PhD candidates and shared research infrastructure.
• University of Turku (Finland)coreStrategic or Co-development PartnerInternational research collaboration on intestinal flora and infection risk. Followed over 10,000 people for 6 years studying gut bacteria composition.
• Amsterdam Skills CentercoreStrategic or Co-development PartnerSeparate entity where surgeons and operators from around the world practice surgical skills. Provides 24/7 access to simulation training without patients.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amsterdam-neuroscience-amsterdam-umc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amsterdam UMC - Amsterdam Neuroscience